Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | NSD2 | O96028 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22806019 | 0.83 | CYP1A2 (0.59) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL20218242 | 0.83 | CYP1A2 (0.59) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL29759335 | 0.83 | CYP1A2 (0.59) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL9285698 | 0.78 | CYP1A2 (0.46) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL13442892 | 0.78 | TDP2 (0.63) | GAANSD2CES1TDP2ABL1 | |
| SCHEMBL21994233 | 0.76 | CYP1A2 (0.51) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL18822112 | 0.76 | MAPT (0.59) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL30088112 | 0.76 | CYP1A2 (0.51) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL5178865 | 0.75 | CYP1A2 (0.80) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL5937366 | 0.75 | CYP1A2 (1.00) | CYP1A2SMN1; SMN2MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379549-B1 | 7-AZAINDIRUBINS, 7'-AZAINDIRUBINS, 7-7'-DIAZAINDIRUBIN AND THE CORRESPONDING 3'-OXIME ETHER DERIVATES: PRODUCTION THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT | EISENBRAND GERHARD (DE) | 2016-09-21 | — | — | EP | claimed |
| EP-2379549-A1 | 7-AZAINDIRUBINS, 7'AZAINDIRUBINS, 7,7'-DIAZAINDIRUBINS AND THE CORRESPONDING 3'-OXIME ETHER DERIVATIVES THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT | Eisenbrand, Gerhard (DE) | 2011-10-26 | — | — | EP | claimed |
| WO-2010072399-A1 | 7-AZAINDIRUBINS, 7'AZAINDIRUBINS, 7,7'-DIAZAINDIRUBINS AND THE CORRESPONDING 3'-OXIME ETHER DERIVATIVES THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT | EISENBRAND GERHARD (DE) | 2010-07-01 | — | — | WO | claimed |
| EP-2199292-A1 | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament | Technische Universität Kaiserlautern (DE) | 2010-06-23 | — | — | EP | claimed |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2025-09-23 | — | — | US | disclosed |
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4222142-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-113461680-B | 4-hydroxycoumarin azaisatin derivative and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022071484-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2022-04-07 | — | — | WO | disclosed |
| CN-109438323-B | Gossypol-7-N heteroisatin Schiff base compounds with anti-tumor activity and synthesis method thereof | 陕西盘龙药业集团股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-109575050-B | Gossypol-7-N heteroisatin Schiff base compounds with anti-tumor activity and synthesis method thereof | 陕西盘龙药业集团股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-113461680-A | 4-hydroxycoumarin azaisatin derivative and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2021-10-01 | — | — | CN | disclosed |
| US-20080119515-A1 | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6117885-A | Biphenyl-substituted quinoline derivatives | E. R. SQUIBB & SONS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-5441955-A | Tuberculosis | PATHOGENESIS CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
| WO-1995013807-A1 | INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
| EP-0556060-A1 | Biphenyl-substituted quinoline and naphthyridines derivatives as angiotensine II antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | CYP1A2 807/4885SMN1; SMN2 3921/4885MAPT 3799/4885 |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CYP1A2 807/4885SMN1; SMN2 3921/4885MAPT 3799/4885 |
| US-20080119515-A1 | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | MAP3K20, MAP3K1, MAP3K19 | CYP1A2 3408/4885SMN1; SMN2 3844/4885MAPT 2038/4885 |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CYP1A2 966/4885SMN1; SMN2 4313/4885MAPT 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.